A patient who has been taking an SSRI tells the nurse that the drug has caused reduced sexual performance, weight gain, and sedation. The nurse will suggest that the patient ask the provider about using which drug?

Initiation of Antipsychotics requires close monitoring for cardiovascular and neurological side effects due to their impact on dopamine, histamine, and alpha-adrenergic receptors. Many antipsychotics can cause vasodilation and impaired autonomic regulation, leading to blood pressure instability. Early adverse effects are most prominent during the initial dosing period. Preventing falls and syncope is a key nursing priority during the start of therapy.

Rationale:
A. Bradycardia is not a common primary concern with antipsychotic initiation. While some medications may indirectly affect heart rate, they mostly cause tachycardia or blood pressure changes rather than clinically significant slowing of the heart. Monitoring heart rate is important but not the highest priority compared to orthostatic changes.

B. Hypertension is not a typical adverse effect of antipsychotic medications. Many antipsychotics are more likely to cause hypotension due to alpha-adrenergic blockade. Therefore, elevated blood pressure is not the primary concern during early therapy.

C. Orthostatic blood pressure is the most important parameter to monitor because antipsychotics commonly cause orthostatic hypotension. This occurs due to alpha-1 adrenergic receptor blockade, leading to vasodilation and impaired compensatory vascular response when standing. It increases the risk of dizziness, syncope, and falls, especially during initial dosing or dose escalation.

D. Abdominal distention is not a primary early safety concern with antipsychotic initiation. While gastrointestinal side effects such as constipation can occur, they are not as immediately dangerous as cardiovascular instability. Orthostatic changes pose a more urgent risk requiring early monitoring.

Opioid tolerance develops with repeated use of medications such as Morphine, leading to a reduced response to the same dose over time. This occurs due to neuroadaptive changes at opioid receptors and downstream signaling pathways. As tolerance increases, higher doses are required to achieve the same therapeutic effect. However, tolerance develops unevenly across different opioid effects.

Rationale:
A. Increased respiratory depression is not expected with tolerance because patients typically develop tolerance to respiratory depressive effects over time. While respiratory depression is a major risk in opioid-naïve individuals, chronic users often require higher doses to produce the same effect. However, this does not eliminate risk, especially with dose escalation.

B. Increased euphoria is not associated with tolerance; instead, tolerance generally reduces the euphoric effects of opioids. Repeated exposure leads to diminished reward response, contributing to dose escalation in some individuals seeking the initial effect. The neurobiological adaptation reduces sensitivity to opioid-induced pleasure.

C. Decreased constipation is incorrect because tolerance develops poorly to gastrointestinal effects of opioids. Constipation persists due to continued reduced gastrointestinal motility from mu-receptor activation in the gut. Patients often require ongoing bowel regimens despite long-term opioid use.

D. Decreased analgesic effect is the hallmark of opioid tolerance. Over time, the same dose produces less pain relief due to receptor desensitization and downregulation. This necessitates higher doses or alternative pain management strategies to maintain adequate analgesia.